Compare BMR & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMR | FEMY |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.3M | 22.4M |
| IPO Year | 2021 | 2021 |
| Metric | BMR | FEMY |
|---|---|---|
| Price | $1.28 | $2.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | 26.4K | ★ 67.0K |
| Earning Date | 08-11-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,293,313.00 |
| Revenue This Year | $0.19 | N/A |
| Revenue Next Year | N/A | $328.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 40.77 |
| 52 Week Low | $1.06 | $0.29 |
| 52 Week High | $3.24 | $6.29 |
| Indicator | BMR | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 37.40 |
| Support Level | N/A | $0.41 |
| Resistance Level | N/A | $3.21 |
| Average True Range (ATR) | 0.00 | 0.17 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 0.00 | 27.12 |
Beamr Imaging Ltd provides content-adaptive video compression solutions for human viewing and machine vision. The company is trusted by technology companies such as NVIDIA and Amazon Web Services, and serves media companies including Netflix, Paramount, and JioHotstar. Using Emmy-winning patented technology, its solutions help deliver media content with high quality while reducing storage and delivery costs. Its customers include over-the-top content distributors, video streaming platforms, and Hollywood studios that use its products to store, distribute, and monetize video and images across devices. The company operates in the United States, Israel, and the rest of the world, with the United States generating maximum revenue.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.